Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7864136 | 1.00 | MAOA (0.33) | MAOAMAOBHTR6BCHEADRA2B | |
| SCHEMBL7865410 | 1.00 | MAOA (0.33) | MAOAMAOBHTR6BCHEADRA2B | |
| SCHEMBL7865686 | 0.80 | RET (0.36) | MAOAMAOBHTR6PDPK1CHRNA7 | |
| SCHEMBL7864073 | 0.80 | RET (0.36) | MAOAMAOBHTR6PDPK1CHRNA7 | |
| SCHEMBL14326116 | 0.66 | DPP4 (0.32) | HTR6 | |
| SCHEMBL8262640 | 0.65 | BACE1 (0.32) | HTR6 | |
| SCHEMBL10505019 | 0.65 | IDO1 (0.42) | MAOAMAOBHTR6BCHEADRA2B | |
| SCHEMBL6227622 | 0.63 | IDO1 (0.41) | MAOAMAOBHTR6BCHEADRA2B | |
| SCHEMBL10384222 | 0.63 | AKR1C3 (0.47) | — | |
| SCHEMBL10929426 | 0.60 | DRD2 (0.47) | MAOAMAOBHTR6BCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359303-B2 | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor | PURDUE RESEARCH FOUNDATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20120041018-A1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010124005-A1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041018-A1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | DBH, SLC6A3, SLC18A2 | MAOA 222/4885MAOB 112/4885HTR6 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.